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Abstract
I study several aspects of the value in performing oncology clinical trials
using screening biomarkers to preferentially select and enroll responders.
From trial reports and investigational reports on potential biomarkers, I
construct a series of six cases comparing the trial as conducted to a
hypothetical trial using different screening and eligibility criteria. These
cases illustrate, within limits of the model, what difference the use of a
plausible biomarker test may have on trial size, cost, number of patients
screened, and number of patients exposed to experimental treatment without
benefit.
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Valuation of the use of biomarkers predictive of drug
efficacy to enrich responders in oncology drug clinical
development.
This thesis aims to quantify part of the value derived from utilizing a
biomarker in the clinical testing of an oncology drug. In particular value
obtained from use of a biomarker predictive of drug-efficacy or -resistance to
enrich for better clinical effect in the population studied. The value, in human
and financial terms, can come from several sources. Those benefits with
which I am concerned here are
* to enroll fewer patients, and so reduce the size of the trial,
* to expose fewer patients to experimental treatment without benefit,
* to reduce the duration of the trial.
Reference trials compared with hypothetical trials using
biomarkers
To quantify these benefits I analyze a series of reference cases. Each of
these references is a clinical trial of an oncology drug for which there is or
may be a biomarker predictive of efficacy or resistance. For each reference I
posit a certain change to the trial-either adding a biomarker when none was
used, or using a different biomarker, or taking one away when one was used.
Typically I create the hypothetical case from trial results and a report of an
investigation into the predictive value of a potential biomarker. An example
of such an investigation is an evaluation of PTEN deficiency as a marker of
resistance to trastuzumab [1].
The point is that whichever of the reference or hypothetical case selects
patients to get greater effect, that case will be able to show its effect at the
same confidence levels while enrolling a smaller number of patients.
Cases will be detailed below; briefly the drugs and clinical applications are
· trastuzumab, metastatic breast cancer
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* tamoxifen, metastatic breast cancer
* erlotinib, non-small cell lung cancer
Biomarkers in these cases
By biomarkers I mean any test at all which can provide new information
about a patient's likelihood to respond to treatment. Practically proteomic
tests and expression tests are avenues of development. The tests used in
the cases reported here are tests for expression, immunohistochemistry
(IHC), fluorescence in situ hybridization (FISH), and a measure of cell
proliferation. Other tests such as tests of methylation, reported race, and
gender all fall within the scope of biomarker for this discussion.
Oncology
A word about the interest of predictive biomarker tests in cancer and cancer
drug development:
Cancers carry genetic changes, often many, some of which have proven to
be characteristic of prognosis or sometimes instructive in treatment. An
example is BCR/Abl, a fusion gene, and tyrosine kinase protein characteristic,
even defining of chronic myeloid leukemia (CML).
As for imatinib, lately developed to inhibit BCR/Abl in CML, tamoxifen for
blockade of the estrogen receptor (ER) has been used in the US since 1977
for breast cancer [2].
Understanding that the etiology of cancer is genetic, we may expect that
some cancers are different from others in ways that can guide treatment, as
a result of the particular genetic changes that have been dealt to the cells of
the malignancy.
patient selection for established treatments
Patient selection for established treatments is clear and well defined when
the use of a drug inhibiting a single target proves to be successful, and when
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that target is overexpressed or constitutively active. This is so with Her2 as
target of trastuzumab and biomarker for predicted efficacy of treatment in
breast cancer. And is so with BCR/Abl as target of imatinib and biomarker in
CML. And with the estrogen receptor as target of tamoxifen and biomarker
in breast cancer.
patient selection for investigational drugs
But patient selection is not always clear for new prospective drugs. Gefitinib
had very low response rates, and in odd populations. It was granted
accelerated approved for non-small cell lung cancer after phase II results but
has had its labeling amended and its use cut back after failing to show
survival benefit. Gefitinib inhibits by intention the epidermal growth factor
receptor (EGFR), also called variously erbB1 or Herl, which is part of a
homologous family of signal transduction proteins involved in growth, and
found disregulated in cancers.
A correlation of EGFR expression and efficacy of gefitinib was investigated,
but did not prove to be, although particular mutations related with sensitivity
to gefitinib have been reported.
EGFR as a target of cancer treatment
As an emblematic example of a cancer therapy target, EGFR has monoclonal
antibodies targeting its cell surface epitopes and small molecule tyrosine
kinase inhibitors targeting its intracellular region. Like Her2 EGFR is a cell
surface protein. As of 2005 as reported in [3] these antibodies (biologics)
and drugs were in development or in marketing for Her-1 (EGFR) and Her-2
(Table 1, Table 2):
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Agent Characteristic Target Tumor Type Stage
Cetuximab Chimeric HER-1 Colon H&N, Marketed
NSCLC, pancreas Phase III
ABX-EGF Human HER-1 Colon, renal Phase III
EMD-7200 Humanized HER-1 H&N, ovarian, Phase II
colon, cervix
h-R3 Humanized HER-1 H&N Phase II
Pertuzumab Humanized HER-2 Breast, ovarian, Phase II
prostate, NSCLC
Trastuzumab Humanized HER-2 Breast Marketed
Table 1. Her2
from [3]. H&N,
family monoclonal antibodies in development or marketing. Table
head and neck; NSCLC, non-small-cell lung cancer.
Tyrosine Kinase Inhibitors Designed to Target the HER Family
Agent Irreversible Target Tumor Type Stage
Gefitinib No HER-1 NSCLC Marketed
Erlotinib No HER-1 NSCLC, Marketed
pancreas
Lapatinib No HER-1/2 Breast Phase III
CI-1033 Yes Pan HER SCC, skin Phase II
EKB-569 Yes HER-1 Colon Phase II
BMS-599626 No HER-1/2 - Phase I
AEE788 No HER-1/2 Anti-VEGFR - Phase I
Table 2. Her2 family small molecule tyrosine kinase inhibitors. Table from [3].
SCC, squamous cell carcinoma; NSCLC, non-small-cell lung cancer.
value to select patients for greater effect
In treatment, it is of course critical to the lives of patients to know what
treatments are most likely to bring benefit. But before a drug has become
approved for marketing, it becomes important to know which patients are
most likely to benefit from its use. This is so for the same human terms as
in treatment with marketed drugs, and for the principle of not wishing to
expose patients to experimental treatment without promise of benefit. But in
clinical development-with its major impact on drug development expense-
effective patient selection promises savings in cost and time.
These are the reasons for this investigation into the value of patient selection
to improve response in trials, and why in oncology.
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Approach
The rough method of analysis is to collect data on the effect of the treatment
in a reference case, with or without biomarker as the case may be. I
propose different trial eligibility so the treated subgroups in the reference
case and the hypothetical case will have different effects from treatment
(effect usually as response rate). To keep the same p value and power of
between the studies, the sample size will change. It is the ratio of these two
sample sizes which is a primary result in the case.
The choice to utilize a biomarker to select patients implies costs and other
considerations; these are many, variable, and bear discussion. A few are
costs to develop the biomarker test, for its validation, deployment and use,
and considerations toward marketing and adoption of the drug. And some
other potential benefits may also attend the choice, such as earlier
marketing, competitive advantage of higher efficacy rates, useful patent life,
revenue from the biomarker test itself, and potentially improved chances of
regulatory approval.*
My main intent in this analysis is to quantify just several of the putative
benefits-how the decision to use biomarkers may influence trial size and by
extension its cost, trial duration, and patients treated without benefit.
Point of view
It's important to note that I am only making this investigation on drugs
which did ultimately gain regulatory approval. Before making choices of
clinical trial design, one would not know whether treatment for the indication
in question would be ultimately approvable. The value of using a biomarker
to select patients for enrollment will depend on which of the two types of
therapy it turns out to be, approvable, or not. For example, the value
obtained by the extension of useful patent term would not apply to both
approvable and non-approvable therapies. Savings in the cash costs of the
* By construction each of the reference and hypothetical case has the same chances
of showing effect. This is not the same as achieving regulatory approval, which one
can argue is more likely in case the effect of treatment is larger.
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trial would apply to both. I place this aspect of valuation-prospectively
considering drugs which will ultimately fail-outside my scope, primarily
because data are sparse on drug development failures.
I draw on Vernon and Hughen's working paper [4] on the economics of
pharmacogenomics, on Simon and Maitournam's work on the efficiency of
targeted trial designs [5] and on Manke et al. [6] in which this general
analysis method was earlier used.
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The cases
Trastuzumab trials without Her2 as a biomarker
Two main cases follow in the use of trastuzumab, in treatment of metastatic
breast cancer. The reference case is from a phase III study [7] enrolling 938
metastatic breast cancer patients, with eligibility open to those testing for
Her2 with an immunohistochemical (IHC) score of 2 or more (IHC2+).
I study several hypothetical cases in comparison to this reference. The first
and second suppose that testing for Her2 was not to have been required for
enrollment.
Trastuzumab trials with Her2 and PTEN
The third case on the same reference trial supposes now the use of a
biomarker predictive of resistance, to be used in addition to Her2 testing.
This biomarker is modeled with data from a report on the use of PTEN
deficiency as a marker of resistance to trastuzumab [1]. A fourth variation is
studied of an incremental improvement to the PTEN test, using PTEN plus a
Her2 test with better specificity.
Tamoxifen, in the treatment of metastatic breast cancer.
This case applies a report of a potential biomarker to the prospect of
selecting invasive breast cancer patients least likely to relapse under
treatment with tamoxifen. The potential biomarker is progesterone receptor
(PgR) status measured with and tumor proliferative status measured
with 3H-thymidine labeling index (TLI)
Erlotinib, in the treatment of non-small cell lung cancer
Erlotinib is a small molecule EGFR inhibitor, has been approved for the
treatment of non-small cell lung cancer. The erlotinib trial showed EGFR
expression to have predictive value. These data are used to construct a
hypothetical trial in which patients are enrolled who have overexpression of
EGFR.
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Table 3. Summary table of
studied.
drugs, their drug targets, and cancers used in the cases
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Drug Brand Drug Type Target Cancer Type
Name
erlotinib Tarceva tyrosine kinase EGFR non-small cell lung
inhibitor (TKI) (Herl) cancer
(erbBl)
trastuzumab Herceptin mAb Her2 invasive and
(neu) metastatic breast
(erbB2) cancer
tamoxifen Nolvadex competitive estrogen invasive and
anti-estrogen receptor metastatic breast
(ER) cancer
Ethical Stance
In considering the decision to use predictive biomarkers, each choice entails
ramifications: commercial, clinical, ethical. I discuss the ethical nature of the
decision, exploring several factors which may become significant when one
considers a particular drug development case.
I'll define the decision under ethical consideration as this:
To decide whether to use a predictive biomarker test in an oncology
clinical trial, with a rationale to select subjects for an expectation of
greater effect.
In cases where a feasible choice exists to use a predictive biomarker to
enrich responders, is it ethical to do so? Is it ethical not to do so? One's
answer will depend on the particular situation. Here I bring out several
considerations which might bear on the decision, with the intention that
these considerations would serve as a framework with which to examine a
particular situation.
The decision bears not only on clinical trials, but clinical practice post-
marketing should the drug be approved.
patients exposed to trial
One kind of ethical value holds in exposing fewer patients to trials.
One measure of the risk patients engage might simply be the number of
patients in the experimental treatment group, the fewer the better if
effectiveness can be shown.
This number of people are exposed to experimental treatment, and so take
the risk the drug will not be effective for them. Any selection criteria that
increase effect will be preferable on this score.
Another measure, which one can make once the trial has been conducted, or
which one can guess at before, is the number of individuals exposed to
experimental treatment without benefit. This is the value quantified in the
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cases presented here, which mitigate toward the choice of using a biomarker
for selection.
Society and individuals only accept the risk of lack of efficacy and adverse
effects for the chance the treatment will come into practice. And when the
treatment does not come into practice, if we could have known, we would
rather not have done the trial.
risk of drug failure
It is preferable to avoid both
· false rejection of an effective drug, and
· false acceptance of an ineffective drug.
In the case of false rejection, there are two ills-patients are exposed to
trials uselessly, and a good drug will not later be available to treat patients.
In the case of false acceptance, patients are exposed to trials of an
ineffective drug, and patients later on will be treated with an ineffective drug.
How can the use of predictive biomarkers affect the likelihood of false
rejection and false acceptance? In the analysis presented here, the
probability of type I and type II errors are fixed so the biomarker and non-
biomarker cases were comparable. This does not mean that in practice the
likelihood of approval will be the same when a trial shows efficacy.
There can be several influences which may make a trial with fewer patients
and greater effect more likely to achieve approval. For one, trial sponsors
may in practice power the biomarker trial higher, in a trade-off between cost
and risk of false rejection. Also, given that statistical significance has been
reached, one may suspect that approval is more likely if effect is greater,
because of the greater potential benefit to patients of the drug. These
factors mitigate toward using a biomarker test for patient selection.
A trial less likely to be falsely rejected is to be preferred in this from an
ethical viewpoint.
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creation of orphan populations
Selection of drug candidates must take into account the size of the ultimate
market for those drugs. When considering a collection of targeted
treatments, in aggregate this effect could create a set of less served cancer
patients. As the groups of unserved patients become small niches, it follows
that they will generate less interest by industry.
Whereas regulatory agencies promote the development of drugs for orphan
indications, it seems unlikely that the orphan niches which might come into
being on the fringes will be seen as orphan indications. Incentives provided
by regulatory authorities to promote development of orphan drugs would not
apply to these populations.
It is not necessarily so that such an outcome, creating unserved niches, is
unethical or inappropriate. It may be considered that these unserved niches
exist either way, whether they are recognized or not.
For a drug that has an association between effect and biomarker status, that
association will exist whether or not the fact of it is known, and whether or
not drug prescribing is based on such biomarker status. So consider the
outcome in each of the clinical trial kinds-with patients selected on the basis
of biomarker and not. Suppose a biomarker selected trial yields a drug
approval, and creates an "orphan population" of patients for whom the drug
is not demonstrated to work. In the case of a drug approved after a non-
selected trial one may argue that the "orphan population" is still the same
population, only now we don't recognize them as less likely responders.
The full force of this argument is weakened when we consider that we will
know more about the likely non-responders if we have tested the drug on the
full population, and this may provide better guidance to the treatment of
biomarker positive individuals. Even given some patients' negative
biomarker status they may still be best off taking the drug, only we may not
know this to be so if a biomarker were used as a selection criterion in trials.
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lower response may not mean the drug is not clinically
significant
While trials may be made more efficient by selecting patients more likely to
respond, it might happen that even those biomarker negative individuals who
are less likely to respond would still find that their best choice is treatment
with the drug. When this is the case and when targeted trials are conducted
there is risk of harm to the biomarker negative population.
When trials exclude biomarker negative patients one can expect the drug to
be approved only for biomarker positive patients. This will in turn affect
health provider policies and physicians' prescribing practice.
One may hope that following initial approval for a narrow indication, further
trials might be done, to widen approval for other indications. But they may
not, and I view further trials as if they may not be made, from our vantage
point for ethical analysis at the point of decision on how to design a single
clinical trial. Or physicians might prescribe the drug off-label, if they have
evidence it is the best choice for some biomarker negative patients.
The key difference, perhaps, if a targeted trial is conducted, is that
physicians and regulators would have no data from this trial on the response
of biomarker negative individuals. If the biomarker negative population has
lesser response, yet still clinically significant response, one might never know
based on the targeted clinical trial.
Here is a risk of harm to the biomarker negative population, in case they
have clinically significant response to the drug. If a pooled trial were to have
been conducted, the biomarker negative population would be approved and
prescribed for treatment with the new drug, and would benefit. If a targeted
trial were to have been conducted, these same individuals would not have an
approved treatment, and their physicians would not have evidence of the
drug's benefit.
While there is commercial incentive to make trials smaller, there is also
significant incentive to keep indications wide. The best thing that can be said
14
about this risk of harm to excluded patients is that drug companies have a
strong interest to reach for wider indications, at the time of initial clinical
trials and in follow-on applications. This interest counterbalances the
incentive to make trials smaller, and blunts the tendency toward exclusion.
cases where exclusion criteria vary together with race or
ethnic group
One ethical concern may arise in the circumstance that one race or ethnic
group is highly represented among those excluded from trials, and then later
treatment, according to biomarker status. On the one hand it may be
unethical to test the drug on biomarker negative individuals who appear less
likely to respond. On the other hand we would rather not leave a racial or
ethnic group underserved.
use of a response biomarker for to screen for continued
treatment
Use of a biomarker may avoid some of the objections against, in the case
that the biomarker for selection is in fact a biomarker for response to
treatment. It could be possible, for example, to try an experimental
treatment on enrollees in the trial, and keep for study only those for whom
an imaging study shortly after initiation of treatment shows that the
treatment is acting on the tumor. It can be hoped that this sort of screening
may be more specific for response, but statistical likelihood aside, such a
screen may be seen as more fair.
where is the biomarker negative patient better off?
One lens on the decision is to consider the individuals who are biomarker
negative, indicating they have a lower likelihood of response, and the
prospect of including them in a trial which doesn't use a biomarker for
selection.
If what one believes about the biomarker and its relation to response implies
biomarker negative patients are better off with the control group treatment,
one may argue that a trial using a biomarker should be considered.
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commercial feasibility of biomarker test
Suppose a biomarker test can clearly distinguish patients likely to respond
from those unlikely to respond, yet can not be feasibly implemented in
clinical practice. In such a case, it would be hard to argue for approval of the
drug to be used without the biomarker. Then trials would have to be
conducted without using the biomarker for patient selection. However, if trial
sponsors or physicians conducting the trial can know who will not respond,
can a trial ignoring this information be ethically conducted? The answer may
depend on what alternatives are available for the biomarker negative group.
The main concern I see when this situation occurs is that drug companies will
have incentive to avoid gathering more data showing the relationship of
biomarker status to response.
how to handle uncertainty
How should we treat uncertainty in the quantities that form the context for
the decision to use a predictive biomarker? How narrow should our
estimates be before considering a trial using the biomarker? These estimates
are uncertain-biomarker prevalence, drug response conditioned on
biomarker status, even knowledge that the drug is at all effective. At the
time of clinical drug development, we expect more often to be unsure of
these values than to know them well.
One (somewhat dissatisfying) approach to this question is to make the
evaluations underlying the decision not only given one's best estimates, but
also while varying estimates within reasonable ranges. If the extremes of
such evaluations all point toward the same decision, one may feel more
comfortable. However, in case the extremes point toward opposite decisions
(which I consider more likely), there is little additional guidance to be gained
from the exercise.
further trials when biomarkers are used for control and
experimental drug
Tricky issues of trial design are raised if standard of care treatment has
different inclusion/exclusion criteria than experimental. In essence the
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populations in the control group and experimental group are different when
different biomarkers are used to establish eligibility for each treatment.
If standard of care were to demand the use of the established
biomarker/drug, and the novel drug uses a different biomarker then certain
problems arise in the design of the trial. How are subjects to be selected for
randomization? Select without the biomarker and include/exclude after
randomization? Then the experimental and control populations would be
composed differently, and measurement of treatment effect over control
would be spurious. Select only those who are positive for the biomarkers
needed for both of the treatments? Then the control and experimental
groups are composed the same but the population studied would not be
representative of the population meant to be treated.
summary
This discussion of ethical concerns mostly lend support to the use of
predictive biomarkers for patient selection, yet exposes certain hazards to
the approach. It is hoped that analysis of a particular drug development
program in the light of the issues discussed here will provide some guidance
in this decision.
17
Modeling sample size
I follow some of Vernon and Hughen's terminology (Table 4) [4] and use
Simon and Maitournam's sample size equations to determine the first result
of this model, PBR, (Table 5) the sample size ratio-the ratio between the size
of a trial in which only biomarker positive patients are enrolled and the size
of one in which the biomarker test is not performed.
Proportion of the population for whom biomarker test is
positive
Efficacyt for those without biomarker, above control.
6 Improvement in efficacy among positive biomarker
population.
EB =(E+,) Efficacy rate in the biomarker positive population, above
control.
ER =(s+2) Efficacy rate in pooled population of positive and negative
biomarker test, above control.
a Probability of rejecting the null hypothesis when it is true.
That is, the chance of concluding that the treatment is
effective if it has no effect or if it is deleterious. This is
required to be .05 typically.
P Probability of failing to reject the null hypothesis given it is
false. That is, the chance of failing to show efficacy for a
treatment that does have the expected effect. Often (1- 13) is
described as the power of a trial. In practice I take 3 to be
typically 0.1
Table 4. Symbols from [4] for the calculation of sample sizes in a reference trial
versus a related hypothetical case.
A statement of the relation between required trial size and effect (and a
and p), in the terms of Vernon and Hughen [4], is
N=(±I11J(Za +ZfJ)
Equation 1. Relation between sample size,a, f,, and effect. [4]
t Efficacy in these definitions refers to the treatment groups, usually as response
rate, above control.
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Simon and Maitournam use a more sophisticated sample size equation, and
perhaps more closely following practice. I adopt this equation, shown fully
in Appendix A. *
In my analysis I pick N andE from a trial report. Using the
characteristics of some contemplated biomarker, I estimate the effect which
would follow in the use of such a biomarker to select patients. The relative
sample sizes of the targeted to the untargeted trials is a main result.
NB
PBR N
NR is the size and ER is effect from a reference trial; I propose a value of the
effect EB in a hypothetical trial; and from these obtain the corresponding
sample size of a trial using the biomarker, NB.
I provide by construction that a and 8 are each the same between actual and
hypothetical trials.
PBR The sample size ratio, between the sample size required to
demonstrate effect in the biomarker positive population and the
sample size to demonstrate effect in the pooled biomarker
positive and negative population.
NR The number of patients required to detect the effect +X6, in the
pooled population of biomarker positive and negative, with the
parameters a and f3, without using biomarker for eligibility.
NB The number of patients required to detect the effect +6, with the
parameters a and 3, while using the biomarker for eligibility.
Table 5. Symbols used to model changes in trial size.
* Both sets of sample size equations yield results that are mostly similar but vary by
as much as 17%.
§ The actual trial data form the reference case. Characteristics of a contemplated
biomarker form the hypothetical case. I abuse this language in the first example in
which it is reversed-a hypothetical trastuzumab trial considered to have been done
without Her2 as an eligibility criterion.
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Scope and validation of the model
Such a model as I present, to estimate value that would be gained in a
hypothetical trial in comparison to a reference trial, is meant to illustrate.
The reference cases and biomarker characteristics are chosen to create a
plausible comparison. In any actual particular case of a new trial the
equations underlying this model would be applied using values relevant to
that case. In practice other considerations outside this model would certainly
be part of the analysis.
Validation
In validating a model, one would ideally wish to
a) ensure the model is calculating what it is meant to calculate without
error, that it matches a distinct statement of what the model does.
b) compare with any independent implementations of the algorithm.
c) note where the model breaks down, what it does and doesn't take into
account; consider assumptions which may be violated and so introduce
error.
d) compare with any independent estimates of a similar type.
e) compare the results of the model's predictions with actual outcomes.
Of course there is the final bulwark against a renegade error, the critical
reader.
detecting potential errors in model's behavior
The model takes a few inputs from the two cases to be compared, the
reference trial and the hypothetical one in which a different selection criterion
is used to select patients more likely to respond to treatment. The main
intermediate result is the ratio of the two sample sizes. Outputs depend on
this and others of the inputs.
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The model is described in the preceding section and in following sections. To
assure the model is acting reasonably, I reproduced a few synthetic cases
developed by Simon and Maitournam [5].
I also ran a series of synthetic data on the author's website,
http://linus.nci.nih.gov/~simonr/boep.html. These results matched mine
down to the tolerance of integer rounding.
Samples of the synthetic data used in this validation are found in Appendix B.
testing versus an independently developed implementation
I also ran a series of synthetic data on the author's website,
http://linus.nci.nih.gov/~simonr/boep.html. These results matched mine
down to the tolerance of integer rounding.
Samples of the synthetic data used in this validation are found in Appendix B.
limitations and scope of the model
There are assumptions made in the model which are not always (often?)
correct, and these cause systematic error, or bias. Assumptions, their
violation, and its effect on the results are discussed along the definition of
the model, and in the sections of relevant cases.
Even within the scope of this model, there are some assumptions of the
model at variance with full reality; these bear some consideration.
One assumption is that the control group will have the same outcome
independent of whether the trial is done with the biomarker. This is untrue
generally (but with an effect unknown to us). I note later in the case of Her2
in breast cancer in what way the resulting estimates should be in error
because of this assumption.
Another assumption made in [4] is that control group effect is 0. The
equations used here, from [5], do not make this assumption.
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compare with any independent estimates
The only closely related estimate I know of is on a powerpoint slide [8] by
Art Levinson as CEO of Genentech. In this a claim is made on the value
obtained by using Her-2 to select patients for trastuzumab-Appendix C. In
this appendix I compare this statement with my results.
compare predictions with actual outcomes
One of the very attractive approaches to validating a model is to compare it's
predictions with later outcomes. However, it is not desirable, feasible, or
ethical to test the same drug for the same indication with targeted and non-
targeted trial designs.
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Modeling reduction in cost
I use the cost of a single patient in a cancer clinical trial to be $10676 in
2005 dollars, based on an estimate of $9000 in 1998 [9], and inflated by the
consumer price index [10].
Vernon and Hughen [4] argue that trial costs form a preponderance of the
cost of drug development, so that (NR-NB) /NR = I-PBR (Table 6) approximates
the reduction in trial costs and development costs overall, when using the
biomarker test to select patients.
I-pBR =(NR-NB)INR Variable reduction in trial costs, of biomarker case
versus reference.
cv = (NR-NB)x Variable cost savings from smaller trial size.
<single patient cost>
Table 6. Variable reduction in trial costs.
Modeling the number of patients screened
Any benefits from being able to make earlier development decisions or from
earlier marketing depend on the duration of clinical trials. The duration of
trials will depend in part on the number of patients treated, but also on the
number of patients who are screened, and their availability.
Fewer patients enrolled, assuming the number of clinical trial centers remains
unchanged, implies a shorter enrollment time and so a shorter trial time. *
However, depending on the proportion of the population for whom the
biomarker test is positive () more patients may have to be screened.
Whether having to screen more patients leads to a longer trial time depends
critically on the rate that new patients become available, and whether more
trial centers are opened. This question will be idiosyncratic, depending on
the incidence rate of the cancer, the catchment size of the centers, and the
particulars of the eligibility requirements. Rather than making weakly based
assumptions I model this question as far as identifying the number of
** I neglect the time to make the biomarker screening, but this should be considered
in practice.
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patients screened, as NB/ X (Table 7) [4, 5]. The number of patients
screened in the reference case is trivially NR.
NB/IX The number of patients screened in the biomarker case.
Table 7. Screening size of trial.
Modeling the difference in patients treated without benefit
When comparing a reference trial with a hypothetical case, I report my
estimate of the difference in the number of patients exposed to experimental
treatment without benefit. I admit this may be a fuzzy concept; even so this
is how I define it here:
* I assume that the control group is getting standard of care (half of
those enrolled by assumption), and for this reason I count none of
them in this estimate. The numbers treated in each case are NRx0O.5
and NBx0O.5.
* I treat effect for a single patient to be binary, so that a treatment
effect of 60% in a group is taken to mean 40% of the patients do not
benefit.
* Those patients given the experimental treatment without effect in the
reference case are NRxO.5x(l-ER). Those in the biomarker case
NBXO.Sx(1-EB).
NAFailT= The expected number of biomarker negative
O.Sx((]-E)xNR - (I-EB)xNB) patients treated with the experimental treatment
who do not benefit.
Table 8. The difference in number of patients treated without benefit.
NziFai7, is what I define as the difference in number of patients exposed to
experimental treatment without benefit (Table 8). A large number means
that the biomarker+ selection spares many individuals from treatment
without benefit.
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Case modeling format
This diagram and table summarize what the biomarker test means in the
context of population of eligible patients and their response to treatment. As
a whole it represents the reference trial in which both biomarker + and -
groups are treated in their proportion in the population. Effect is net of
control group effect.
F biO tr arkerlnt. Su '-
" flail treatment, S succeed
0.28
.10
.13
65%
22%
7%
S
+
+
F
F
S
6%
trastuzumab Her2 IHC+ v none
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The inputs and outputs of the model are shown in the case table.
drug name, biomarker condition 1 v. condition 2
2 proportion biomarker+
6 efJicacy /br biomarker-, net of control(5 ____z__ ef Jficacy fbr biomarker+
EB (s-+t) efficacy for biomarker+, net of control
ER (E+) efficacy or pooled biomarker +/-, net of control
treatment effect in control group
treatment effect in biomarker-
treatment effect in biomarker+
PBR sample ratio
NB sample size biomarker case
NR sample size no-biomarker case
NB/ patients screened to find biomarker+
VNR-NB)INAR _% reduction in variable cost
Cv variable cost savings
NAFaITX _ patients saved failure under treatment
P(-isucc eea sensitivity ofthe biomark-er test
P(-Afail) specficit of the biomarker t est
Some figures are filled in directly or after some calculation, from clinical trials
and biomarker studies. These input values are entered in the left of the
column; and values that descend from these, to satisfy the relations of the
model, are entered in the right of the column.
NR or NB may be taken from the reference case, or NR is arbitrarily set to 1000
to illustrate the ratio.
A note on what is meant here by "efficacy" or"effect." Effect is represented
as a proportion, measured in different ways, in keeping with the clinical trial
reports. Data from the cases studied here use variously complete response,
partial response, objective response rate, five year relapse-free survival, and
overall survival. Response is used synonymously. In this model of clinical
trials, the null hypothesis is that the experimental treatment group and
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control group effect are not different (two sided). There is usually no
placebo, but rather standard of care treatment for the control group.
Computations of sample size use effect net of control group effect. , NB, and
NR all refer to effect above control. Equation 1 uses effect in the sense of net
effect.
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Trastuzumab trials without Her2 as a biomarker
I now consider the hypothetical case in which trastuzumab is imagined to
have been tested without using the Her2 biomarker.
A phase III trial studied the use of trastuzumab plus chemotherapy versus
chemotherapy alone in Her2-overexpressing metastatic breast cancer [11].
treatment condition N rate of
response
trastuzumab plus anthracycline 143 56%
anthracycline 138 42%
trastuzumab plus paclitaxel 92 41%
paclitaxel 96 17%
trastuzumab plus chemotherapy 235 50%
chemotherapy 234 32%
Table 9. Phase III results for trastuzumab plus chemotherapy versus chemotherapy
alone in Her2-overexpressing metastatic breast cancer. Her2-overexpression was
determined as IHC 2+. [7, 11]
Pooling together each of the trastuzumab treated groups, compared to no
trastuzumab:
treatment condition N rate of
response
trastuzumab 470 50%
no trastuzumab 468 27%
Table 10. Response rate pooled across treatment subgroups in pivotal phase III
trial.
All patients enrolled in these trials had Her2 over-expression of IHC 2+.
Since Her2 is reported to be overexpressed in 25-30% of metastatic breast
cancer[12], I take X for 27.5%. We know the effect in the biomarker positive
population, from Table 10; this is (+6), 50%. The population size NB, 938 is
also from Table 10.
We do not, from this phase III study, know , the efficacy of trastuzumab
plus standard of care for breast cancers which don't express Her2. Paclitaxel
monotherapy in other studies gave response rates of 21% to 68% in
metastatic breast cancer. [12] This implies should be something above
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21%, but this is probably an underestimate, if only because of false negative
Her2 assays, and because Her2 is prognostic for negative outcome with
chemotherapy.
One phase II study examined clinical outcomes associated with the various
Her2 assays. This study enrolled a group who were positive and a group of
patients who were negative for Her2 expression [12]. The overall response
for IHC+ patients was 69%, and for IHC- patients response was 46%. Thus
from that study £* = 46%, (*+6*) = 69%, and so 6* = 13%. If we adopt 6 =
8* = 13%, directly we get these values:
bionmarker + /-
fiJil treatmenl, S succeed
E
6+8-
+
+
0.28
.10
.23
65%
22%
7%
S
F
F
S
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trastuzumab Her2 IHC+ v. none
2 0.28 proportion biomarker+
6 10% ejficacvJor biomarker-, net of control
6 13% A efficacy for biomarker+
EB (e+-) 23% efficacyfor biomarker+, net of control
ER (6+26) 14% efficacy for pooled biomarker +,/-, net of'control
27% treatment effect in control group
3 7% treatment effect in biomarker-
50% treatment effect in biomarker+
PBR 0.38 sample ratio
NB 938 sample size biomarker case
NR 2490 sample size no-biomarker case
NB/2 3350 patients screened to find biomarker+
(R-NB /NR 62% % reduction in variable cost
Cv $16,566, 726 variable cost savings
NAFailTx 714 patients saved failure under treatment
P(-succeedj 0.47 sensitility of the biomarker test
P(4 fail) 0. 75 specifici) of'the biomarker test
Case 1. Trastuzumab trial as conducted with Her2 biomarker compared with open
enrollment.
A similar analysis in [6] based on different sources forms the basis for the
inputs to this case:
- S I 
__OI
i iohmarker I- 
I fil reatment, S succeed I 
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trastuzumab Her2 IHC+ v. none (a)
I I I
A 0.34
6 7%
6+6 9%
- F 61%
+F 29%
- S 5%
trastuzumab Her2 IHC+ v. none (a)
A 0.34 proportion biomarker
E 7% efficacyfor biomarker-, net of control
a 9% A efficacyfor biomarker+
EB (£+6) 16% efficacy finr biom arker+, net of 'control
ER (-+2) 1 0% efficacyfor pooled biomarker +/-, net of control
29% treatment effect in control group
36% treatment effJct in biomarker-
45% treatment effct in biomarker+--
PBR 0.42 sample ratio
NB 469 sample size biomarker case
NR 1122 sample size no-biomarker case
NB/A 1379 patients screened to.find biomarker+
NR -NB) INR 58% % reduction in variable cost
Cv $6, 971, 662 variable cost savings
NAFailTx 308 patients savedafilure under treatment
P(+succeed) 0.54 sensitivit, of 'the biomarker test
P(fail) 0.68 specificity of the biomarker test
Case 2. Trastuzumab trial as conducted with Her2 biomarker compared with open
enrollment, from Manke et al. [6]
In both these cases the trial using the biomarker was less than half the size.
What is really remarkable, though, is the number of individuals screened
relative to the size of the trial. In each case the enrollment would ultimately
be around one third of the screened population. Generally speaking a large
number to screen may mean a considerably longer enrollment period, or
more centers with their attendant cost.
Screening size, remember is strongly dependent on A, as simply NB/2.
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PTEN deficiency as a biomarker of trastuzumab resistance
It has been reported that PTEN deficiency contributes to trastuzumab
resistance, in vitro, in animal xenograft, and in a small group of cancer
patients [1]. This case compares the reference case mentioned above,
trastuzumab for metastatic breast cancer, conducted using Her2 IHC2+ as a
biomarker, with a hypothetical trial using PTEN inactivation as additional
marker of resistance, enrolling only Her2 IHC2+ PTEN+ patients.
Treatment effect is 65.8% (Table 11). Frequency of PTEN IRS5+among the
Her2+ study participants was 38/47 so I take the probability of finding a
patient to test biomarker+ to be 0.81. The control group response is taken
to be the same as in the reference, 27%. Biomarker negative now means
Her2 IHC2+; response in this population is 50% from the reference trial.
(Case 3).
PTEN status Response Rate
deficient (IRS 0-4) 11.1%
positive (IRS 5+) 65.8%
Table 11. Response rate for PTEN deficient and positive patients. Cutoff for
positive PTEN assessment at immunoreactive score (IRS) 7+. Response as complete
response or partial response.
Biomarker Proportion of IHC2+ who are
also PTEN IRS5+
PTEN- IRS 0-41Her2 IHC2+ 11/47
PTEN IRS 5+lHer2 IHC2+ 38/47
Table 12. Proportion of Her2 IHC2+ study participants who are PTEN+ and PTEN-.
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biomarlwr +/-
F fail treatment. S slucceed
trastuzumab Her2 lHC+ PTEN+ v. Her2+
2. O 0.81 proportion biomarker+
6 | 23% efficay for biomarker-, net of control
8 16% A efficacy for biomarker+
EB (ef-) 39% efficacy/br biomarker+, net of'control
ER (+S) 36% efficac, for pooled hbionarker -+/-, net of control
27% treatment effect i control group
50% treatment efJt in biomarker-
66% treatment efict in biomarkler+
PBR 0.85 sample ratio
NB 802 sample size biomarker case
NR 938 sample size no-biomarker case
NB/ _ 991 patients screened to find biomarker+
(NR-NB)/R__ 15% % reduction in variable cost
Cv $1,456,693 variable cost savings
NAFailTx 56 patients saved failure under treatment
P(+Isucceed) 0.88 sensitivitv of the biomnarker test
P(-Vfail 0.23 specificiht of the biomarker test
Case 3. Hypothetical trastuzumab trials using biomarker of HER2 IHC+ plus PTEN
activity.
Selection based on PTEN in this example yields an incremental improvement
over Her2 IHC2+. Although response is higher among the biomarker+ group
in this case (16% higher), the overall reduction in variable cost is modest
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I trastuzumab Her2 IHC+ PTEN+ v. Her2 IHC+
A 0.81
.6 23%
E+6- 16%
- F 15%
+ F 49%
- S 4%
(15%). This is attributable in part to the small proportion of the patients less
likely to respond who are excluded (19%).
PTEN deficiency with a more stringent Her2 test
When Her2 expression is measured with fluorescence in situ hybridization
(FISH), the specificity of the PTEN+ Her2+ biomarker test is even greater.
This hypothetical case supposes enrollment criteria of PTEN IRS5+ Her2
FISH+, compared with the reference case using Her2 IHC2+ as above.
Response rate is 71% for patients with this biomarker. (Table 13). The
probability A of finding biomarker+ is taken to be the compound probability of
FISH+ I Her2 IHC2+ (39/47), and PTEN IRS5+ I FISH+ (31/39) (Table 12
and Table 14).
Biomarker response rate
PTEN- (IRS 0-3) Her2 IHC2+ FISH+ 12.5%
PTEN IRS4+ Her2 IHC2+ FISH+ 71%
Table 13. Response rate is strikingly lower among Her2 FISH+ PTEN-, compared
with Her2 FISH+ PTEN+[1], or Her2 IHC2+ .
Biomarker Proportion of IHC2+ who are
also Her2 FISH+
FISH+ Her2 IHC2+ 39/47
FISH- I Her2 IHC2+ 8/47
Table 14. Proportion of Her2 IHC2+ study participants who are FISH+ and FISH-.
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trastuzumab .Her2 FISH+ PTEN+ v. .Her2 IHC+
biomarker +,/-
F ftail treatment. S succeed
0.66
23%
21%
26%
37%
8%
S
+
+
F
F
S
29%
trastuzumab .Her2 FISH+ .PTEN+ v. .Her2+ IHC2+
2 0.66 proportion biomarker+
E 23% efficacojbr biomarker-, net of control
3 21% efficacyfor biomarker+
EB (+) 44% efficacy for biomarker+, net of control
ER (6+,) 37% efficacy fr pooled biomarker +/-, net of 'control
27% treatment effect in control group
50% treatment efjfect in biomarker-
71% treatment ejfect in biomarker-+-
PBR 0. 70 sample ratio
NB 661 sample size bioncarker case
NR 938 sample size no-biomarker case
NB/, 1002 patients screened to find biomarker+
(NR-NB)INR 30% % reduction in variable cost
Cv $2,955,807 variable cost savings
NAFailTx 111 patients saved filure under treatment
P(+ succeed) 0. 79 sensitivity othe biomarker test
P (-fail) 0.42 specificity of 'the biomarker test
Case 4. Hypothetical trastuzumab trials using biomarker of
compared with trial as conducted using Her2 IHC2+.
Her2 FISH+ PTEN+
Replacing Her2 IHC2+ with Her2 FISH+ yielded an improvement of 30% in
savings versus 15% (Case 3). This difference is attributable in large part to
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the exclusion of more patients less likely to respond, and in a smaller degree
to the marginally higher response rate among biomarker+ patients.
Note that these are both cases in which the number of patients screened is
close to the reference population for the pooled biomarker +/- trial.
A practical note on the validity of this biomarker: The evidence in [1] for
PTEN inactivity as a marker of clinical resistance is thin; this limits our
confidence that the estimation parameters used as inputs to the model are
even close to true. The magnitude of the predictive value of PTEN activity,
though, is large, and source of a considerable benefit as modeled.
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Tamoxifen for invasive breast cancer
This case applies a report of a potential biomarker to the prospect of
selecting invasive breast cancer patients least likely to relapse under
treatment with tamoxifen.
The anti-estrogen drug tamoxifen was first approved for the treatment of
metastatic breast cancer in postmenopausal patients in the United Kingdom
in 1973 and subsequently in the United States in 1977 [2]. Prior to this,
removal of the ovaries (or ablation) was performed to treat breast cancer,
the first report of which was in 1896. [13, 14] Tamoxifen is used today in a
number of breast cancer indications.
The study by Scarpi, et al. [2] aimed to investigate the relationship between
outcome in node positive estrogen receptor-positive (ER+) invasive breast
cancer patients treated with tamoxifen and the status of several potentially
relevant pre-treatment biomarkers. In particular, in this study, progesterone
receptor (PgR) and tumor proliferative status measured with 3H-thymidine
labeling index (TLI) using were found in multivariate analysis to have
independent value to predict relapse (Table 15).
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Table 15. Relapse free survival for subgroups determined by presence of
progesterone receptor and by proliferative index [2].
Five year relapse-
free survival (RFS)
group size
Biomarker Status
overall
75%
119/119
PgR+/TLI-
87%
62/119
PgR-/TLI- or PgR-/TLI+
PqR+/TLI+
66% 29%
62%
57/119
Table 16. Relapse-free survival at five years for the study group and subgroups
divided by biomarker status.
This case presents something of a problem because the trials leading to the
development of tamoxifen would have been conducted in a different
regulatory and overall health care context than trials we could propose
today. There is no suitable reference trial to select from. For reference
purposes, I propose that we are comparing the development of tamoxifen, as
if it were new, with a standard-of-care that has one half of tamoxifen's effect
as demonstrated in these clinical results.
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As in the case with PTEN, assuming these data do indicate a true predictive
association of the biomarker, those values are probably somewhat different
than the values I extract here. In using these data (Table 16) for this case
analysis I do not imply that our confidence in the predictive value of these
biomarkers is strong enough for one to make clinical or drug development
decisions on this foundation. Nor did the authors make such a claim. In
practice validation will come with successive trials measuring the biomarker.
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tamoxifen ER+ PGR+ TLI- v. ER+
I ~~ ~~ ~~I I I
A 0.52
.6 124%
E+6 25%
- F 36%
+ F 26%
- S 12%
Iel
tamoxifen ER+ PGR+ TLI- v. ER+
A2 0.52 proportion biomarker+
E 24% efflcacfor biomarker-, net of'control
8 25% A efficacy for biomarker+
EB (e+-8) 50% efficacyfor biomnarker+, net of control
ER (£+6) 38% efficacyfor pooled biomarker +/-, net of control
38% treatment effct in control group
62% treatment effect in biomarker-
87% treatment effect in biomarker+
PBR 0.54 sample ratio
NB 543 sample size biomarker case
NR 1000 sample size no-biomarker case
NB/A 1043 patients screened to find biomarker+
(NR-NB)/NR 46% % reduction in variable cost
Cv $4,875,411 variable cost savings
NAFaiITx 175 patients saved failure under treatment
P(+Isucceed) 0.69 sensitivity of the biomarker test
P(-fail) 0.58 spec ificity of the biomnarker test
Case 5. Hypothetical tamoxifen trial comparing all patients
biomarker subgroup, PgR+/TLI-.
with best responding
A dramatic reduction in seen in sample size when adding the hypothetical
biomarker test, the variable cost savings is 39%.
The control treatment effect was contrived for this case to be half the
tamoxifen reference response. If one substitutes more effective treatment
for the controls, the gains in efficiency are improved (Table 17).
40
% savings
in variable
cost
42%
44%
45%
46%
46%
48%
50%
Sensitivity of %cost savings over a range
of control effect in the case:
tamoxifen ER+ PGR+ TLI- v. ER+
60%
IA
M 55%
.-
'A 50%
0
e 45%
40%
15% 25% 35% 45% 55%
control treatment effect
Table 17. Cost savings shows modest sensitivity in this case to control group effect.
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25%
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Erlotinib for advanced non-small cell lung cancer
Erlotinib, an EGFR inhibitor, has been approved for the treatment of
advanced or metastatic non-small cell lung cancer. These data are taken
from the approval summary [15]. Although EGFR expression was not shown
to be a good predictor of response to treatment with another EGFR inhibitor
gefitinib, the erlotinib trial did show EGFR expression to have predictive
value.
Table 18. Tumor response
placebo groups [15].
(complete response or partial response) in treated and
N Effect
EGFR- 61 3.28%
EGFR+ 69 11.6%
Unknown 294 9.52%
Table 19. Tumor response (complete response or partial response) in treated group
according to EGFR status [15].
This set of data presents two difficulties for inclusion. One is that EGFR
status is known in a subset of patients. This "over-determines" the values
for effect in the biomarker positive, negative, and pooled population. I make
an estimate for these (Table 20) taking care to give priority to the effect in
the (largest) unknown biomarker group.
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N Effect
erlotinib 424 8.96%
placebo 210 0.95%
Group N Effect
estimated EGFR- 294*61/130 = 138 =(3.28/9.52)*8.96%
in unknown =3.09%
estimated EGFR+ 294*69/130 = =(11.6/9.52)*8.96%
in unknown 156 =10.92%
known+estimated 138+61=199 =(3.09%*199+61*3.28%)/199
EGFR- =4.10%
known+estimated 156+69=225 =(10.92%*156+69*11.6%)/225
EGFR+ = 11.1%/
Pooled 424 8.96%
Table 20. Reconciling the known and unknown EFGR status of the treatment group.
I assume that EGFR status in the unknown group is in the same ratio as in the
known, and apportion the effect in the pooled group according to the ratio of effect
in the known EGFR+ and EGFR- subgroups.
The second difficulty is that the placebo group is not the same size as the
treatment group, in contradiction to an assumption of the model. For the
purpose of the model I force the size of the placebo group to match the
treatment group.
A contradiction to an assumption in the model which would affect model
results is that EGFR+ status in the control group is a marker of poor
prognosis [15]. (The model assumes control group effect is the same in both
the reference and hypothetical case.) This implies that in a trial enrolling
only EGFR+ patients the treatment effect will be easier to show, making any
differences shown in the model more conservative than they should be.
However, since control effect is so close to zero, I don't believe the distortion
is significant.
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biomarker +-/-
F firil treatment. S succeed
erlotinib EGFR+ v. none
A O0.53 proportion biomarker+
E 3.2% eJficacyjbr biomarker-, net of control
8 7.0% A eJicacvfor biomarker+
EB (+-) 10% efficacy for biomarker+, net ofcontrol
ER (+2A6) 6.9% efficacy fbr pooled biomarker +1/-, net of 'control
1. 0% treatment effect in control group
4.1% treatment effect in biomarker-
11.1% treatment efect in biomarkr-+
PBR 0.62 sample ratio
NB 527 sample size biomarker case
NR 848 sample size no-biomarker case
NB/2 994 patients screened to find biomarker+
(NR-NB)VNR 38% % reduction in variable cost
Cv $3,422,584 variable cost savings
NAFailTx 158 patients saved filure under treatment
P(+succeed) 0.78 sensitivity o 'the bioniarker test
P(-[fail) 0.49 specificit) of the biomarker test
trial to one in which
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erlotinib EGFR+ v. none
I .
A 0.53
£ 3.2%
e+6 7.0%
- F 45%
+F 48%
- S 1%
Case 6. Hypothetical erlotinib trial comparing the reference
only EGFR+ patients are enrolled.
Discussion
The quantitative results are summarized here:
Table 21. Case summary. Variable cost reduction. Example: costs of $80M with
biomarker versus $100M without is said to measure a 20% variable cost reduction.
Another component of trial size is the number of patients screened in the biomarker
trial to find the requisite number of biomarker positive patients to randomize. This is
meaningful in relation to the number of patients screened in an untargeted trial.
Patients saved failure under treatment is the expected difference, in the targeted and
untargeted design, of the patients given experimental treatment who will not benefit
from it.
A wide range is not a surprise, as biomarker prevalence, and treatment
response conditioned on biomarker status vary widely among the cases,
along with other factors.
worth of one biomarker over another
Comparisons between choices of biomarker are interesting, such as with this
case
· trastuzumab Her2 IHC+ PTEN+ v. Her2 IHC+
and this one
trastuzumab Her2 FISH+ PTEN+ v. Her2 IHC+,
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patients patients
variable screened to patients savedscreened incase cost find trial without failure
reduction biomarker + biomarker under
patients treatment
trastuzumab Her2 IHC+
v. none 62.3% 3350 2490 714
trastuzumab Her2 IHC+
v. none (a) 58.2% 1379 1122 308
trastuzumab Her2 IHC+ PTEN+
v. Her2 IHC+ 14.5% 991 938 56
trastuzumab Her2 FISH+ PTEN+
v. Her2 IHC+ 29.5% 1002 938 111
tamoxifen ER+ PGR+ TLI-
v. ER+ 45.7% 1043 1000 175
erlotinib EGFR+
v. none 37.8% 994 848 158
which compare designs using progressively more refined biomarkers.
It is remarkable to me how the substitution of FISH for IHC in those cases
can wring an extra 15% enrollment size reduction, 2 9 .5% variable cost
savings with FISH versus 14.5% with IHC. However the inputs to the model,
the biomarker values were chosen from literature as plausible, not well
supported; so it would be prudent to hold some suspicion that the values are
way off base.
screening size
Targeted trials which are hungry for many patients to screen are those in
which
a) biomarker positive patients are relatively rare.
b) the drug has a small improvement of effect over control treatment.
A trastuzumab trial held as a reference case would be more than twice larger
if it were to have been done without using a biomarker; but it would have
screened 25% less patients.
I have mentioned that in some cases the assumption that the control group
in the biomarker and the reference case have the same effect is incorrect. In
the case of Her2 for breast cancer, it is clearly incorrect, because Her2 is a
poor prognostic indicator [16]. In that case which compares the trial as
conducted versus the hypothetical case in which no biomarker was used
(Case 1), the effect of this poor assumption is to attribute worse prognosis to
the control group in the hypothetical no biomarker case than we truly expect.
This leads to an overestimate of effect in the untargeted case. In the end,
the error causes the model's value for savings to be an underestimate.
In the case where we compare the Her2 IHC2+ biomarker with Her2 FISH+,
the assumption probably does not cause as large an inaccuracy, since one
may expect the two control populations to be more alike in their response.
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Appendix A.
The sample size equations used in this work, excerpted from [5].
The Ury and Fleiss expression for the sample size of the
untargeted design is:
n = (nJ4)[l + kw + 1
where
n = [z. i;;7 + z /p,(l - P.) + 1p4 - )]
rP = Pc + ,
P (Pc + p,)/2,
= I - p, and
w = B/[(z + zp)pq ].
The constants z. and z denote the 100 (-a) and 100 (I-P3)
percentiles of the standard normal distribution.
For the targeted design we add the symbol T. The response
probability in the experimental group is p = p, + 68 and the
expression for the sample size becomes:
r
= (na/4)[ I + x/I + 2w] 2
where.=la [z, pPs1 + C07( I -p,')]) + 2/ 
PT = eP + p.)/2.
qT = I -PT and
7 = A,4(z + ) '7qi.
The relative efficiency of the two designs with regard to number
of randolnized patients is therefore given by equation (A) with
f ( defined by
./'1<pq + z ,y( I - p9,) + p,t I - ,.) I + 1 + 2w
.
2 1'-7,qr + C,3 \tt i + j -+ -x + 
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A Rosetta stone relating the terms used in this model to
from Simon & Maitournam[5].
the formulas I use
correspondence
term used to Simon &
here example Definition Maitournam
0.28 proportion biomarker+ 1-y
__________ 10% efficacy br biomarker-, above control So
S 13% A efficacy for biomarker+ 51 - So
EB (£Sf) 23% efficacyfor biomarker+, above control 51
14% treatment effect in control groupPc
27% treatment effect in biomarker- group Pc+So
37% treatment effect in biomarker+ group Pc+-S
efficacyfor pooled biomarker +/-, above
ER (e+S) 50% control So (y) + S1 (1-y)
PBR 0.57 sample ratio / (n / nT)
NB 938 N biomarker case
NR 1658 N no-biomarker case
NB/2 3350 patients screened to find biomarker+
(NR-NB)/NR 43% % reduction in variable cost
Cv $7,687,791 variable cost savings
NAFaiITx 355 patients saved ilure under treatment
P(+ succeed) 0.47 sensitivity of the biomarker test
P(-Vail) 0.75 speci icity of the biomarker test
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Appendix B.
Validation samples
This table shows an example of some of the synthetic data that was run
through the website associated with [5]. tt
Pc 0.2 0.3 0.3 0.2 0.2 0.2 0.2
y 0.5 0.3 0.3 0.5 0.5 0.5 0.5
SI 0.3 0.3 0.3 0.4 0.4 0.4 0.4
So 0 0.2 0.2 0.2 0.2 0.2 0.2
a 0.05 0.05 0.05 0.05 0.05 0.005 0.0005
/P 0.1 0.1 0.01 0.2 0.1 0.1 0.1
See appendix A for symbol definitions. The calculation of the model
presented here and from the website agreed down to the tolerance of integer
rounding errors.
The following examples are synthetic data used in [5]. The results from my
model match the website calculator results, and to the tolerance of visual
inspection, match the results published in [5].
Pc 0.1 0.0.1 0.5 0.5 0.1 0.1 0.5 0.5
y 0.5 0.5 0.5 0.5 0.4 0.4 0.4 0.4
S/ 0.2 0.4 0.2 0.4 0.2 0.4 0.2 0.4
So 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
a 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
fP 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
tt http://linus.nci.nih.gov/~simonr/boep.html
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Appendix C.
This slide by Art Levinson, as CEO of Genentech, states that the value of
performing the trastuzumab clinical trials using Her2 as a predictive
biomarker was faster approval of a $2.5 billion drug, and a $35 million
reduction in trial costs.
source: [8]
with Her2 without Her2
('actual trial) (hypothetical trial)
number of patients 470 2200
response rate 50% 10%
years offollow-up 1.6 10
Although based on a different trial data, it is interesting to compare the
estimates of savings reported here with this estimate from Genentech.
50
The sample size ratio of 470/2200 = 0.21 reported by Levinson compares
with 0.38 in the case examined here. The variable cost reduction estimated
in my model is $16.6M, based on a sample size of 938. This is a great deal
less than the $35M stated by Genentech.
Note that the stated reduction in follow-up time, given the market value of
the drug, far outweighs the reduction in clinical trial costs. Although few
drugs have even close to this commercial value, this result implies that this
source of value should be carefully modeled in practice.
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Exploratory charts
cost reduction ratio over lambda and delta
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